Developer docs
API playgroundTry for free, no card

Search company profiles

Synergenics

Full company profile

uuid0022d3i

Namestring
Synergenics
Legal namestring
Synergenics, LLC
Websiteurl
synergenics.net
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Synergenics, LLC is a San Francisco-based private investment firm founded in 2012 by William J. Rutter, the co-founder of Chiron Corporation. The firm operates as a consortium of commonly-owned yet independently managed biotech companies representing the Rutter estate and foundation, providing strategic capital, shared laboratory facilities, and experienced management and administrative services to early-stage life sciences ventures. Following founder Rutter's death on July 11, 2025, the company transitioned to professional management under CEO Sebastián Bernales and CIO Francisco Dopazo.

The firm's core offering is a shared-platform model designed to lower the operating overhead of early-stage biotech ventures. Member companies receive financial support, access to shared laboratory facilities, and centralized management and administrative services (human resources, compliance, record-keeping) through a four-person Synergenics operating team, while each portfolio company retains scientific autonomy over its own proprietary domains. The consortium spans 19 named biotech companies across therapeutic (Bluejay Therapeutics, Quince Therapeutics, Pyxis Oncology, Toreador Therapeutics, Praxis Biotech, Vettore Biosciences, Centaurus, Soley Therapeutics, Trancura Biosciences), diagnostic (Nuclein, Ilytica, Hegenomics, PhenoBiome), vaccine (Omvax), synthetic biology (Ansa Biotechnology, Kainomyx, Invitria, ProLynx), and venture (Humboldt Fund) categories.

Synergenics generates returns through its investment in the consortium; pricing of investment and management services is not publicly disclosed. Distribution is relationship-driven, with inbound inquiries received via the firm's website and handled with stated response times of up to four weeks. No external limited-partner base or institutional fund structures are disclosed; the firm's capital base is anchored in the Rutter foundation. Co-investment relationships include Humboldt Fund and Droia Genetic Diseases Fund, where Synergenics leadership holds General Partner and Venture Partner roles respectively.

Short descriptiontext

Synergenics is a San Francisco-based private investment firm operating a consortium of 19+ commonly-owned yet independently managed biotech companies, providing strategic capital, shared laboratory facilities, and management services to early-stage life sciences ventures backed by the Rutter foundation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech venture capital, life sciences investment, biotech consortium platform, startup incubation services, biotech portfolio management
Industry5 codes
PRIMARYBPAGAKAA
Private Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotech Venture Capital and Investment Management
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Investment returns and portfolio company support
TypeSubscription Recurring
Description

Synergenics generates returns through its investment in a consortium of independently managed biotech companies. The platform provides financial support, shared laboratory facilities, and experienced management and administrative services to early-stage life sciences companies, creating economies of scale across the portfolio.

synergenics.net
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Infrastructure, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Synergenics is a private investment firm that operates a consortium of commonly-owned yet independently managed biotech companies. It provides member companies with financial support, shared laboratory facilities, and experienced management and administrative services to accelerate early-stage life sciences development while preserving each portfolio company's scientific autonomy.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Synergenics is a biotechnology-focused private investment firm and venture platform — not a single product company. It operates a consortium of commonly-owned yet independently managed biotech portfolio companies. The firm provides strategic capital, shared laboratory facilities, and management/administrative services to early-stage life sciences companies. Its portfolio spans 19 biotech companies across therapeutic areas including Ansa Biotechnology (enzymatic DNA synthesis), Bluejay Therapeutics (chronic viral and liver diseases), Centaurus (ceramide-driven cardiovascular/metabolic diseases), Hegenomics (blood and cancer screening), Humboldt (venture capital firm), Ilytica (AI-powered molecular diagnostics), Invitria (animal-free cell culture media), Kainomyx (cytoskeletal biology platform), Nuclein (point-of-care molecular testing), Omvax (meningococcal B vaccines), PhenoBiome (microbiome therapeutics), Praxis Biotech (neurodegenerative disease therapeutics), Pro Lynx (protein-drug conjugate technologies), Pyxis Oncology (antibody-drug conjugates), Quince Therapeutics (neurodegenerative/rare diseases), Soley Therapeutics (immune regulation modulation), Toreador Therapeutics (T cell engagers), Trancura Biosciences (genomic immune profiling), and Vettore Biosciences (MCT4 inhibitor for pulmonary fibrosis).

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Synergenics CEO Sebastián Bernales is involved in scientific outreach and education through long-standing involvement with Fundación Ciencia & Vida, a Chile-based foundation focused on science and technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Synergenics CEO Sebastián Bernales is involved in scientific outreach and education through involvement with Fundación EcoScience.

3Merken Biotech
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Synergenics CEO Sebastián Bernales is active in scientific outreach and education through involvement with Merken Biotech.

synergenics.net
4Portfolio Companies Consortium (20+ companies)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Synergenics operates a consortium of 20+ commonly-owned yet independently managed biotech companies including Ansa Biotechnology, Bluejay Therapeutics, Centaurus, Hegenomics, Ilytica, Invitria, Kainomyx, Nuclein, Omvax, PhenoBiome, Praxis Biotech, ProLynx, Pyxis Oncology, Quince Therapeutics, Soley Therapeutics, Toreador Therapeutics, Trancura Biosciences, Vettore Biosciences, and others. These companies benefit from shared laboratory facilities, financial support, and experienced management services.

synergenics.net
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

ARCH is a leading early-stage biotech VC that co-founded and built companies in similar therapeutic areas (synthetic biology, genomics, therapeutics), making it a comparable incumbent investor in the same deal pool.

TypeEmerging player
Description

venBio is a biotech-focused investment firm that partners with entrepreneurs to build therapeutic companies, overlapping with Synergenics' consortium approach to biotech creation.

TypeDirect peer
Description

Roivant operates a hub-and-spoke platform creating and incubating multiple biotech 'Vants' — directly analogous to Synergenics' consortium of commonly-owned but independently managed biotechs.

TypeBroad incumbent
Description

RA Capital is a healthcare-focused crossover and VC investor active in the same early-stage biotech deal flow as Synergenics, often co-investing alongside founders in clinical-stage assets.

TypeDirect peer
Description

Arix is a listed life sciences investment company that builds and supports a diversified portfolio of biotech companies — comparable in structure to Synergenics' consortium platform.

TypeDirect peer
Description

BridgeBio holds a portfolio of multiple therapeutic subsidiaries focused on genetic diseases and rare disorders — the same therapeutic and structural thesis underlying Synergenics' consortium model.

TypeBroad incumbent
Description

Omega Funds is a healthcare-dedicated investment firm focused on early- and mid-stage biotech and medtech — comparable as a professional biotech investor with deep therapeutic expertise.

TypeBroad incumbent
Description

Atlas Venture is a long-standing biotech-focused VC that incubates and builds early-stage life sciences companies — directly comparable to Synergenics' portfolio formation strategy.

TypeDirect peer
Description

PureTech is a listed parent company that creates and holds multiple clinical-stage subsidiaries, mirroring Synergenics' structure of commonly-owned yet independently operated biotech companies.

TypeOthers
Description

Humboldt Fund is a co-investor and strategic partner where Synergenics' CEO is a GP; both firms invest in early-stage biotech and synthetic biology and share deal flow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synergenics

Biotech Venture Capital and Investment Managementsynergenics.net

Synergenics is a San Francisco-based private investment firm operating a consortium of 19+ commonly-owned yet independently managed biotech companies, providing strategic capital, shared laboratory facilities, and management services to early-stage life sciences ventures backed by the Rutter foundation.

What Synergenics does

Synergenics, LLC is a San Francisco-based private investment firm founded in 2012 by William J. Rutter, the co-founder of Chiron Corporation. The firm operates as a consortium of commonly-owned yet independently managed biotech companies representing the Rutter estate and foundation, providing strategic capital, shared laboratory facilities, and experienced management and administrative services to early-stage life sciences ventures. Following founder Rutter's death on July 11, 2025, the company transitioned to professional management under CEO Sebastián Bernales and CIO Francisco Dopazo.

The firm's core offering is a shared-platform model designed to lower the operating overhead of early-stage biotech ventures. Member companies receive financial support, access to shared laboratory facilities, and centralized management and administrative services (human resources, compliance, record-keeping) through a four-person Synergenics operating team, while each portfolio company retains scientific autonomy over its own proprietary domains. The consortium spans 19 named biotech companies across therapeutic (Bluejay Therapeutics, Quince Therapeutics, Pyxis Oncology, Toreador Therapeutics, Praxis Biotech, Vettore Biosciences, Centaurus, Soley Therapeutics, Trancura Biosciences), diagnostic (Nuclein, Ilytica, Hegenomics, PhenoBiome), vaccine (Omvax), synthetic biology (Ansa Biotechnology, Kainomyx, Invitria, ProLynx), and venture (Humboldt Fund) categories.

Synergenics generates returns through its investment in the consortium; pricing of investment and management services is not publicly disclosed. Distribution is relationship-driven, with inbound inquiries received via the firm's website and handled with stated response times of up to four weeks. No external limited-partner base or institutional fund structures are disclosed; the firm's capital base is anchored in the Rutter foundation. Co-investment relationships include Humboldt Fund and Droia Genetic Diseases Fund, where Synergenics leadership holds General Partner and Venture Partner roles respectively.

Synergenics firmographics

Firmographics
Name
Synergenics
Legal name
Synergenics, LLC
Website
https://synergenics.net
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Synergenics is a San Francisco-based private investment firm operating a consortium of 19+ commonly-owned yet independently managed biotech companies, providing strategic capital, shared laboratory facilities, and management services to early-stage life sciences ventures backed by the Rutter foundation.
Ownership category
akta.pro rank

Synergenics industry classification

Industry
Product category
Biotech Venture Capital and Investment Management
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYBPAGAKAA
Private Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Biotech venture capital
  • Life sciences investment
  • Biotech consortium platform
  • Startup incubation services
  • Biotech portfolio management

Where Synergenics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Synergenics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D

Revenue model

  1. Investment returns and portfolio company support: Synergenics generates returns through its investment in a consortium of independently managed biotech companies. The platform provides financial support, shared laboratory facilities, and experienced management and administrative services to early-stage life sciences companies, creating economies of scale across the portfolio.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Synergenics product offering

Product offering

Core offering

Synergenics is a private investment firm that operates a consortium of commonly-owned yet independently managed biotech companies. It provides member companies with financial support, shared laboratory facilities, and experienced management and administrative services to accelerate early-stage life sciences development while preserving each portfolio company's scientific autonomy.

Product overview

Synergenics is a biotechnology-focused private investment firm and venture platform — not a single product company. It operates a consortium of commonly-owned yet independently managed biotech portfolio companies. The firm provides strategic capital, shared laboratory facilities, and management/administrative services to early-stage life sciences companies. Its portfolio spans 19 biotech companies across therapeutic areas including Ansa Biotechnology (enzymatic DNA synthesis), Bluejay Therapeutics (chronic viral and liver diseases), Centaurus (ceramide-driven cardiovascular/metabolic diseases), Hegenomics (blood and cancer screening), Humboldt (venture capital firm), Ilytica (AI-powered molecular diagnostics), Invitria (animal-free cell culture media), Kainomyx (cytoskeletal biology platform), Nuclein (point-of-care molecular testing), Omvax (meningococcal B vaccines), PhenoBiome (microbiome therapeutics), Praxis Biotech (neurodegenerative disease therapeutics), Pro Lynx (protein-drug conjugate technologies), Pyxis Oncology (antibody-drug conjugates), Quince Therapeutics (neurodegenerative/rare diseases), Soley Therapeutics (immune regulation modulation), Toreador Therapeutics (T cell engagers), Trancura Biosciences (genomic immune profiling), and Vettore Biosciences (MCT4 inhibitor for pulmonary fibrosis).

Differentiator

Problem solved

Functional benefit

Companies that use Synergenics

Customer profile

Segments2 records

Ideal customer profiles2 records

Synergenics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Synergenics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Fundación Ciencia & VidaminorStrategic or Co-development PartnerSynergenics CEO Sebastián Bernales is involved in scientific outreach and education through long-standing involvement with Fundación Ciencia & Vida, a Chile-based foundation focused on science and technology.
  • Fundación EcoScienceminorStrategic or Co-development PartnerSynergenics CEO Sebastián Bernales is involved in scientific outreach and education through involvement with Fundación EcoScience.
  • Merken BiotechminorStrategic or Co-development PartnerSynergenics CEO Sebastián Bernales is active in scientific outreach and education through involvement with Merken Biotech.
  • Portfolio Companies Consortium (20+ companies)coreStrategic or Co-development PartnerSynergenics operates a consortium of 20+ commonly-owned yet independently managed biotech companies including Ansa Biotechnology, Bluejay Therapeutics, Centaurus, Hegenomics, Ilytica, Invitria, Kainomyx, Nuclein, Omvax, PhenoBiome, Praxis Biotech, ProLynx, Pyxis Oncology, Quince Therapeutics, Soley Therapeutics, Toreador Therapeutics, Trancura Biosciences, Vettore Biosciences, and others. These companies benefit from shared laboratory facilities, financial support, and experienced management services.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Synergenics competitors and assessment

Company assessment

Broad incumbents

  • ARCH Venture Partners: ARCH is a leading early-stage biotech VC that co-founded and built companies in similar therapeutic areas (synthetic biology, genomics, therapeutics), making it a comparable incumbent investor in the same deal pool.
  • RA Capital Management: RA Capital is a healthcare-focused crossover and VC investor active in the same early-stage biotech deal flow as Synergenics, often co-investing alongside founders in clinical-stage assets.
  • Omega Funds: Omega Funds is a healthcare-dedicated investment firm focused on early- and mid-stage biotech and medtech — comparable as a professional biotech investor with deep therapeutic expertise.
  • Atlas Venture: Atlas Venture is a long-standing biotech-focused VC that incubates and builds early-stage life sciences companies — directly comparable to Synergenics' portfolio formation strategy.

Emerging players

  • venBio: venBio is a biotech-focused investment firm that partners with entrepreneurs to build therapeutic companies, overlapping with Synergenics' consortium approach to biotech creation.

Direct peers

  • Roivant Sciences: Roivant operates a hub-and-spoke platform creating and incubating multiple biotech 'Vants' — directly analogous to Synergenics' consortium of commonly-owned but independently managed biotechs.
  • Arix Bioscience: Arix is a listed life sciences investment company that builds and supports a diversified portfolio of biotech companies — comparable in structure to Synergenics' consortium platform.
  • BridgeBio Pharma: BridgeBio holds a portfolio of multiple therapeutic subsidiaries focused on genetic diseases and rare disorders — the same therapeutic and structural thesis underlying Synergenics' consortium model.
  • PureTech Health: PureTech is a listed parent company that creates and holds multiple clinical-stage subsidiaries, mirroring Synergenics' structure of commonly-owned yet independently operated biotech companies.

Others

  • Humboldt Fund: Humboldt Fund is a co-investor and strategic partner where Synergenics' CEO is a GP; both firms invest in early-stage biotech and synthetic biology and share deal flow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Synergenics social profiles

Digital presence

Synergenics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synergenics leadership team

Management profile

Number of profiles

Profiles4 records

Synergenics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synergenics M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synergenics

What does Synergenics do?

Synergenics is a private investment firm that operates a consortium of commonly-owned yet independently managed biotech companies. It provides member companies with financial support, shared laboratory facilities, and experienced management and administrative services to accelerate early-stage life sciences development while preserving each portfolio company's scientific autonomy.

Is Synergenics a public or private company?

Synergenics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Synergenics founded?

Synergenics was founded in 2012. It employs 11 to 50 people.

Where is Synergenics based?

Synergenics is headquartered in San Francisco, United States, in the North America region.

How does Synergenics make money?

One revenue line is on record: investment returns and portfolio company support.

Who are Synergenics's main competitors?

Broad incumbents on record are ARCH Venture Partners, RA Capital Management, Omega Funds and Atlas Venture. venBio is listed as an emerging player. Direct peers are Roivant Sciences, Arix Bioscience, BridgeBio Pharma and PureTech Health. Humboldt Fund is listed as an others.

Does Synergenics have an API?

No public API is recorded for Synergenics.

What industry is Synergenics in?

Synergenics's product category is Biotech Venture Capital and Investment Management. Its primary akta.pro industry code is BPAGAKAA, Private Foundations, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales